The release of anti-tumorigenic cytokines like IFN-γ, IL6, IL23, IL18, and TNF-α was enhanced in the presence of IL7/IL12 engineered MSCs; these cytokines will likely shift the pro-tumorigenic chronic inflammatory situation to a more anti-tumorigenic acute inflammation capable to sustain an anti-tumor response by CAR T cells and potentially other infiltrating adaptive and innate immune cells [41]. Here, IL18 is linked to neoplasm.